Accretion Nutraveda
Listing performance
Scheduled dates
Tentative timetable — a past date is not confirmation the step completed
Grey market premium
Unofficial and indicative — not a forecast
3 observations recorded — too few to plot a trend.
Day-wise premium · 3 observations
| Date | GMP | % | Sauda | Est. listing | Gain / lot |
|---|---|---|---|---|---|
| 04 Feb 2026 | ₹68 | +52.71% | ₹51,700 | ₹197 | ₹68,000 |
| 03 Feb 2026 | ₹68 | +52.71% | ₹51,700 | ₹197 | ₹68,000 |
| 02 Feb 2026 | ₹17 | +13.18% | ₹12,900 | ₹146 | ₹17,000 |
Gain per lot assumes the premium holds to listing and that the application is allotted — allotment in an oversubscribed issue is a lottery, so it is indicative, not expected. Sauda is the rate paid for a submitted application itself.
Issue details
- IPO date
- 28 Jan 2026 – 30 Jan 2026
- Listing date
- 04 Feb 2026
- Face value
- ₹10 per share
- Issue price
- ₹129 per share
- Lot size
- 1,000 shares
- Issue type
- Book Building issue
- Listing at
- BSE
- Total issue size
- ₹24.77 Cr
- Market cap at offer price
- ₹93.4 Cr
- Promoter holding
- 100.00% → 73.48% pre-issue → post-issue
- ISIN
- INE1KVQ01019
- Registrar
- Kfin Technologies Ltd.
- Lead managers
- Sobhagya Capital Options Pvt.Ltd.
- Registered office
- 27 Xcelon Industrial Park-1, Vasna-Chacharwadi, TaSanand, Gujarat
Reservation and application size
How the issue is split between investor categories, and what each may bid
| Investor category | Shares | % of net | % of total |
|---|---|---|---|
| Anchor investor · within QIB | 5,44,000 | — | — |
| Market maker | 96,000 | — | — |
Application size
Minimum 1,000 shares per lot, in multiples, at ₹129
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 1,000 | ₹1,29,000 |
| S-HNI (min) | 2 | 2,000 | ₹2,58,000 |
| S-HNI (max) | 7 | 7,000 | ₹9,03,000 |
| B-HNI (min) | 8 | 8,000 | ₹10,32,000 |
Category limits
| Category | Bid size | Cut-off |
|---|---|---|
| Retail (RII) | Up to ₹2 lakh | Yes |
| Small HNI (sNII) | ₹2 lakh – ₹10 lakh | No |
| Big HNI (bNII) | Above ₹10 lakh | No |
| Employee | Up to ₹5 lakh | Yes |
Bidding at cut-off means accepting the final issue price without naming one. Only retail and employee applicants may do so.
Anchor investors
Institutional allocation placed a day before the issue opens, carved out of the QIB portion and locked in after listing.
Valuation and performance
Valuation at offer price
₹129 per share
| Metric | Pre-issue | Post-issue |
|---|---|---|
| EPS (₹) | 4.91 | 6.44 |
| P/E (×) | 26.27 | 20.03 |
| Price to book (×) | 8.76 | — |
| Market cap | — | ₹93.4 Cr |
Key performance indicators
Latest reported period
- Return on net worth
- 48.85%
- ROCE
- 36.98%
- Debt / equity
- 0.72
- PAT margin
- 16.33%
- EBITDA margin
- 22.79%
- NAV per share
- ₹14.72
- Price to book
- 8.76
Single period as reported. Year-on-year movement is in the financials table below, where every period is published.
About Accretion Nutraveda
Accretion Nutraveda Limited was incorporated on March 16, 2021 as 'Accretion Nutraveda Private Limited' and converted to a public limited company on May 02, 2025 under the Companies Act, 2013. Headquartered in Ahmedabad, Gujarat, the company operates as a Contract Development and Manufacturing Organization (CDMO) focused on the healthcare sector, manufacturing ayurvedic and nutraceutical products across multiple dosage forms including tablets, capsules, oral liquids, oral powders/churans, external preparations (balms, creams, ointments, gels) and medicated oils. Its portfolio addresses diverse therapeutic categories such as bone and joint care, respiratory care, gynec care, digestive care, cardiac care, liver care, paediatric care, skin and hair care, urinary and UTI care, baby care and memory/neuron care. The company operates from a 10,763 sq. ft. GMP-compliant facility in Sanand, Gujarat, holds ISO, WHO-GMP and Halal certifications, and serves domestic customers as well as export markets including Sri Lanka, Singapore and the USA. Revenue is generated primarily through contract manufacturing on a purchase-order basis from B2B customers including nutraceutical distributors, wellness outlets and merchant exporters, with domestic sales contributing over 96% of revenue. For FY2024-25, the company reported Revenue from Operations of ₹1,600.18 lakh and Profit After Tax of ₹261.28 lakh.
Company Analysis
from DRHPAccretion Nutraveda Limited is a healthcare-focused Contract Development and Manufacturing Organization (CDMO) specializing in ayurvedic and nutraceutical products including tablets, capsules, oral liquids, oral powders, external preparations and oils.
Accretion Nutraveda Limited was incorporated on March 16, 2021 as 'Accretion Nutraveda Private Limited' and converted to a public limited company on May 02, 2025 under the Companies Act, 2013. Headquartered in Ahmedabad, Gujarat, the company operates as a Contract Development and Manufacturing Organization (CDMO) focused on the healthcare sector, manufacturing ayurvedic and nutraceutical products across multiple dosage forms including tablets, capsules, oral liquids, oral powders/churans, external preparations (balms, creams, ointments, gels) and medicated oils. Its portfolio addresses diverse therapeutic categories such as bone and joint care, respiratory care, gynec care, digestive care, cardiac care, liver care, paediatric care, skin and hair care, urinary and UTI care, baby care and memory/neuron care. The company operates from a 10,763 sq. ft. GMP-compliant facility in Sanand, Gujarat, holds ISO, WHO-GMP and Halal certifications, and serves domestic customers as well as export markets including Sri Lanka, Singapore and the USA. Revenue is generated primarily through contract manufacturing on a purchase-order basis from B2B customers including nutraceutical distributors, wellness outlets and merchant exporters, with domestic sales contributing over 96% of revenue. For FY2024-25, the company reported Revenue from Operations of ₹1,600.18 lakh and Profit After Tax of ₹261.28 lakh.
Objects of the Issue
- Purchase of Machineries for Automation in existing Manufacturing unit ₹421.66 Lakhs p.31
- Purchase of Machineries for New Manufacturing Setup ₹803.23 Lakhs p.31
- Funding working capital requirements of our company ₹550.00 Lakhs p.31
- General corporate purposes ₹369.04 Lakhs p.31
Issue Structure
- Total Issue
- Up to 19,20,000 Equity Shares of Face Value ₹10/- each aggregating to ₹2476.80 Lakhs
- Fresh Issue
- Up to 19,20,000 Equity Shares of Face Value ₹10/- each aggregating to ₹2476.80 Lakhs
- Offer for Sale
- NIL
- Price Band
- ₹122 to ₹129 per Equity Share
- Lot Size
- 1000 shares
- Face Value
- ₹10/-
Business Model
The company earns revenue through contract development and manufacturing of ayurvedic and nutraceutical products for third-party clients on a purchase-order basis (B2B CDMO model). It manufactures products across various dosage forms for customers who market them under their own brands, with sales predominantly domestic (96%+) complemented by direct exports to Sri Lanka, Singapore and the USA. It does not have long-term agreements with customers; orders are received on an ongoing purchase order basis.
Business Segments
Promoters
| Name | Role | Pre-Issue | Post-Issue |
|---|---|---|---|
| Mayur Popatlal Sojitra | Promoter | 13.12% | 9.64% |
| Ankurkumar Shantilal Patel | Promoter | 20.00% | 14.70% |
| Paraskumar Vinubhai Parmar | Promoter | 20.00% | 14.70% |
| Hardik Mukundbhai Prajapati | Promoter | 13.12% | 9.64% |
| Harshad Nanubhai Rathod | Promoter | 13.12% | 9.64% |
| Vivek Ashok Kumar Patel | Promoter | 13.12% | 9.64% |
Leadership
Auto-extracted from the company's DRHP using AI, with each fact linked to its source passage (hover any row to see the quote & page). Provided for research only, not investment advice — verify against the official DRHP before relying on it.